Literature DB >> 33324139

The impact of COVID-19 on the WHO FCTC, cessation, and tobacco policy.

Laurent Huber1, Ubaldo Cuadrado2, Raquel Fernandez-Megina2, Martin Raw3, Adriana Blanco Marquizo4, Kelsey Romeo-Stuppy1.   

Abstract

'In the absence of the COVID-19 pandemic, many people in tobacco control worldwide would have been at the Hague, Netherlands, from 9-14 November for the 9th Conference of the Parties (COP9) of the WHO Framework Convention on Tobacco Control (WHO FCTC), advocating for even stronger policies against the tobacco epidemic. The COP has been postponed to 2021, but the pandemic did not stop the global civil society from "virtually" gathering to talk about the WHO FCTC, where it is and where it is going.'
© 2020 2020 Huber L. et al.

Entities:  

Keywords:  COVID-19; WHO FCTC; cessation; tobacco policy

Year:  2020        PMID: 33324139      PMCID: PMC7731301          DOI: 10.18332/tid/130779

Source DB:  PubMed          Journal:  Tob Induc Dis        ISSN: 1617-9625            Impact factor:   2.600


Even in ‘normal’ times, the tobacco industry’s marketing and selling of addictive, lethal products like cigarettes is a leading cause of global illness, resulting in more than 8 million deaths per year. Consequently, they are a major drain on national health systems[1]. This negative impact on society is further exacerbated by the COVID-19 pandemic. After conducting an extensive review of the literature, the World Health Organization released a scientific brief on 30 June in which they concluded that ‘at the time of this review, the available evidence suggests that smoking is associated with increased severity of disease and death in hospitalized COVID-19 patients’[2]. This puts smokers at increased risk during the pandemic. Furthermore, given the growing scientific evidence that COVID-19 is transmitted through aerosols[3], we should keep tobacco in mind when taking measures to stop the COVID-19 pandemic. Thus, it is critical that countries intensify and accelerate implementation of the WHO Framework Convention on Tobacco Control[4]. For example, robust implementation of price and tax measures, mandated in Article 6 of the WHO FCTC, will not only decrease smoking prevalence[5] but also will generate much needed funding during the economic crisis caused by COVID-19. To date, according to the WHO Report on the Global Tobacco Epidemic, 2019, only 38 countries have achieved the benchmark of taxes representing 75% or more of final retail price[6]. Furthermore, while many countries have reported that an increasing number of smokers have expressed an interest in quitting smoking, access to cessation support is highly uneven around the world. According to a 2017 survey on progress in implementation of Article 14 of the WHO FCTC, on tobacco dependence and cessation, two-thirds of the 142 countries that participated in the survey did not even have an official national treatment strategy[7]. As a result, many smokers are unable to get the support they need to quit. Some countries, like Spain for example, have taken some positive steps to protect their citizen’s health by extending smoke-free policies to outdoor areas during COVID-19[8]. But the Spanish government, as well as all governments around the world, could and should do more to take advantage of the WHO FCTC as a tool to advance globally agreed health, development and human rights objectives. This is particularly critical during and after the COVID-19 pandemic.
  2 in total

1.  WHO Framework Convention on Tobacco Control: a key milestone.

Authors:  Haik Nikogosian
Journal:  Bull World Health Organ       Date:  2010-02       Impact factor: 9.408

2.  Progress in implementation of WHO FCTC Article 14 and its guidelines: a survey of tobacco dependence treatment provision in 142 countries.

Authors:  Kapka Nilan; Martin Raw; Tricia M McKeever; Rachael L Murray; Ann McNeill
Journal:  Addiction       Date:  2017-08-02       Impact factor: 6.526

  2 in total
  1 in total

1.  Lifestyle changes of attendees at primary health care centers during the COVID-19 pandemic in Qassim Province, Saudi Arabia.

Authors:  Abdulaziz Almutairi; Chandra Sekhar Kalevaru
Journal:  J Family Med Prim Care       Date:  2021-11-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.